News
Expanding Opportunities for Brain Tumor Research Worldwide
Researchers worldwide now have access to the procedure of growing organoids from fetal brain tissue, which is developed at the Princess Máxima Center. The organoids can be used to model any type of brain tumor in the lab. This allows scientists to generate novel experimental models to study many, often rare brain tumor subtypes. Researchers thus hope to accelerate research into the origin and treatment of brain tumors in children.
Scientists use various models to investigate the biology of healthy tissue and diseases in the laboratory. For example, cell lines, laboratory animals and, for several years now, 3D mini-organs (organoids). These organoids have certain characteristics and are so complex that scientists can accurately mimic an organ's functions in the laboratory. They are therefore used for research purposes, including understanding how cancer can start in a healthy brain, drug sensitivity testing and finding leads for new drugs.
Francesco Andreatta, PhD Student, Artegiani & Hendriks groupBy testing different drugs on the organoids and examining cell viability, we can determine how the cancer cells respond, and which drugs are potential leads for treatment.
Last year, research group leaders Dr. Benedetta Artegiani, Prof. Dr. Hans Clevers and Dr. Delilah Hendriks shared their revolutionary work to grow 3D mini-organs from human fetal brain tissue in the laboratory. Today in Nature Protocols, Artegiani, Hendriks and their colleagues share the method for growing these brain organoids, termed FeBOs, and then adapting them to model a specific type of brain tumor.
DNA alteration
There are many different types of brain tumors in children, many more than in adults. All of these types are rare, so there is little tumor tissue available to use for research. In the protocol published today, the researchers share how CRISPR/Cas9 technology can be used to modify the DNA of some cells within the starting organoid. Thus, if the DNA profile of the tumor type is known, an organoid of a particular type of brain cancer can be generated from this so-called FeBO.
Anna Pagliaro is a PhD student in the Artegiani & Hendriks group and one of the three first authors of the study. She says:
Anna Pagliaro, PhD student, Artegiani & Hendriks groupOne of the strengths of the developed model is that we can investigate how a tumor cell behaves in a healthy environment. This realistic environment makes it possible to investigate, for example, the accelerated growth and behavior of invasion of tumor cells in healthy tissue.
The modified organoids can also be used to test the sensitivity to various drugs. Francesco Andreatta, PhD student and co-first author: 'By testing different drugs on the organoids and examining cell viability, we can determine how the cancer cells respond, and which drugs are potential leads for treatment.'
Roxy Finger, PhD Student, Artegiani & Hendriks groupWe can also see if certain drugs change the behavior of the organoids. For example, their speed of growth or a change in how the cells are arranged in the organoid.
adds PhD student Roxy Finger and co-first author of the study.
In addition, the organoids will also provide important information about the development of brain cancer. At the molecular level, they can offer insight into the change from a healthy cell to a cancerous cell. By sharing the culture protocols with the scientific community, Artegiani and Hendriks hope to help other researchers accelerate their research into new treatments and the origin of brain tumors.
Source original article:
About Princess Máxima Center:
Around 600 children in the Netherlands get cancer every year, and one in four children who are diagnosed with cancer dies from this illness. When a child is seriously ill with cancer, only one thing comes first: cure. That is why at the Princess Máxima Center for pediatric oncology we work together every day in a groundbreaking and passionate way to improve the survival rate and quality of life of children with cancer. Now, and in the longer term. Because children still have a whole life ahead of them. The Princess Máxima Center is not an ordinary hospital, but a research hospital. All children with cancer in the Netherlands are treated here. This makes the Princess Máxima Center the largest pediatric cancer center in Europe. Over 450 researchers and 900 healthcare professionals work closely with Dutch and international hospitals on better treatments and new perspectives on cures. In this way, we give the child of today the very best care and take important steps to improve the chances of survival for the children who are not yet cured.